BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25363400)

  • 1. Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.
    Kaeda J; Ringel F; Oberender C; Mills K; Quintarelli C; Pane F; Koschmieder S; Slany R; Schwarzer R; Saglio G; Hemmati P; van Lessen A; Amini L; Gresse M; Vagge E; Burmeister T; Serra A; Carson A; Schwarz M; Westermann J; Jundt F; Dörken B; le Coutre P
    Leuk Lymphoma; 2015 Jul; 56(7):2105-13. PubMed ID: 25363400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
    Griner LN; Reuther GW
    Cancer Biol Ther; 2010 Nov; 10(10):979-82. PubMed ID: 21084860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
    Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
    Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
    Ito T; Kwon HY; Zimdahl B; Congdon KL; Blum J; Lento WE; Zhao C; Lagoo A; Gerrard G; Foroni L; Goldman J; Goh H; Kim SH; Kim DW; Chuah C; Oehler VG; Radich JP; Jordan CT; Reya T
    Nature; 2010 Aug; 466(7307):765-8. PubMed ID: 20639863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of MSI2 predicts unfavorable outcome in adult B-acute lymphoblastic leukemia.
    Aly RM; Ghazy HF
    Int J Lab Hematol; 2015 Apr; 37(2):272-8. PubMed ID: 25090928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo expansion of normal and chronic myeloid leukemic stem cells without functional alteration using a NUP98HOXA10homeodomain fusion gene.
    Sloma I; Imren S; Beer PA; Zhao Y; Lecault V; Leung D; Raghuram K; Brimacombe C; Lambie K; Piret J; Hansen C; Humphries RK; Eaves CJ
    Leukemia; 2013 Jan; 27(1):159-69. PubMed ID: 22868969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia.
    Thol F; Winschel C; Sonntag AK; Damm F; Wagner K; Chaturvedi A; Göhring G; Schlegelberger B; Lübbert M; Fiedler W; Kirchner H; Krauter J; Ganser A; Heuser M
    Ann Hematol; 2013 Mar; 92(3):315-23. PubMed ID: 23233047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.
    Kharas MG; Lengner CJ; Al-Shahrour F; Bullinger L; Ball B; Zaidi S; Morgan K; Tam W; Paktinat M; Okabe R; Gozo M; Einhorn W; Lane SW; Scholl C; Fröhling S; Fleming M; Ebert BL; Gilliland DG; Jaenisch R; Daley GQ
    Nat Med; 2010 Aug; 16(8):903-8. PubMed ID: 20616797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells.
    Supper E; Tahir S; Imai T; Inoue J; Minato N
    PLoS One; 2015; 10(7):e0134026. PubMed ID: 26218064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
    Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
    J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.
    Beer PA; Knapp DJ; Miller PH; Kannan N; Sloma I; Heel K; Babovic S; Bulaeva E; Rabu G; Terry J; Druker BJ; Loriaux MM; Loeb KR; Radich JP; Erber WN; Eaves CJ
    Blood; 2015 Jan; 125(3):504-15. PubMed ID: 25370416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23).
    Barbouti A; Höglund M; Johansson B; Lassen C; Nilsson PG; Hagemeijer A; Mitelman F; Fioretos T
    Cancer Res; 2003 Mar; 63(6):1202-6. PubMed ID: 12649177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.
    Duggimpudi S; Kloetgen A; Maney SK; Münch PC; Hezaveh K; Shaykhalishahi H; Hoyer W; McHardy AC; Lang PA; Borkhardt A; Hoell JI
    J Biol Chem; 2018 Oct; 293(40):15359-15369. PubMed ID: 30126842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic and functional diversity of phenotypically defined primitive hematopoietic cells in patients with chronic myeloid leukemia.
    Sloma I; Beer PA; Saw KM; Chan M; Leung D; Raghuram K; Brimacombe C; Johnston B; Lambie K; Forrest D; Jiang X; Eaves CJ
    Exp Hematol; 2013 Oct; 41(10):837-47. PubMed ID: 23851302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions.
    Shao L; Miller S; Keller-Ramey J; Zhang Y; Roulston D
    Cancer Genet; 2015; 208(7-8):396-403. PubMed ID: 26186983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.